Overview

Optimizing the Interval Between Cycles of PRRT With 177lu-dotatate in sstr2 Positive Tumors

Status:
Recruiting
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Treatments:
Somatostatin